The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $60.28, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily ...
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) trial of its drug candidate Sotyktu (deucravacitinib) for plaque ...
(RTTNews) - 2seventy bio Inc. (TSVT) agreed to be acquired by Bristol Myers Squibb (BMY) at a price of $5.00 per share in an all-cash transaction. This acquisition values the total equity at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback